Clinical Trials · NCT06771115
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Zomagen Biosciences Ltd.
- Enrollment
- 176
- Start date
- Jan 2025
- Locations
- 14 sites, United States
- Primary endpoint
- Incidence Rate and Severity of Adverse Event (AE), Serious Adverse Event (SAE), and AEs leading to study treatment discontinuation through study completion